Study supports whooping cough booster shot for adolescentsJune 06, 2005Analysis weighs costs, efficacy, disease severity, and vaccine side effects BOSTON- Despite childhood vaccination rates at all-time highs, pertussis (whooping cough) has re-emerged over the past two decades, especially among adolescents, adults, and young infants. Because of this resurgence, federal health policymakers are considering a national booster vaccination program. An analysis by Harvard Medical School researchers in the June issue of Pediatrics offers support for the adolescent booster, concluding that one-time vaccination at 11 years of age may potentially be cost-effective. The Advisory Committee on Immunization Practices, which advises the Centers for Disease Control and Prevention, meets on June 29-30 and will consider pertussis boosters. Combined acellular pertussis vaccines for adolescents and adults are available in Canada, Australia, and Germany. Led by Grace Lee, MD, MPH, Harvard Medical School Instructor of Ambulatory Care and Prevention at the Department of Ambulatory Care and Prevention's Center for Child Health Care Studies, the researchers compared six vaccination strategies, ranging from no vaccination after age 6 to adolescent and adult vaccination with 10-year boosters. The computer simulation model used incorporated existing data on pertussis incidence, disease outcomes, vaccine efficacy, vaccine costs, and side effects. (The Department of Ambulatory Care and Prevention is a unique research and teaching collaboration between Harvard Pilgrim Health Care and Harvard Medical School.) The analysis concluded that one-time adolescent vaccination "would result in significant net health benefits and may be reasonably cost-effective," preventing 36 percent of projected pertussis cases at a cost of $20,000 per quality-adjusted life year saved or $1,100 per case prevented. These estimates - less favorable than those for Haemophilius influenza B (Hib) or measles vaccination, but similar to those for pneumococcal vaccination - were highly sensitive to assumptions about disease incidence, vaccine efficacy, side effects, and vaccine costs, the authors write. "In the past, vaccination programs were cost-saving and life-saving," says Lee, who is also an infectious disease specialist at Children's Hospital Boston. "However, newer vaccines are now focused on reducing morbidity, rather than mortality, and we need to carefully weigh the risks and benefits of vaccination. By balancing the costs of a vaccination program and the potential impact of alternative vaccine policies on reducing disease morbidity and improving quality of life, we can optimize decision making regarding vaccine use in the US." Harvard Medical School |
|||||||||||||||||||||
| Related Vaccination Current Events and Vaccination News Articles Worksite wellness programs may reduce employee absenteeism Emory University Rollins School of Public Health researchers will present Nov. 11 on a range of topics at the American Public Health Association's annual meeting in Philadelphia, including a study that found reduced absenteeism among employees participating in a large-scale worksite wellness program. Poll: Many parents, high-priority adults who tried to get H1N1 vaccine unable to get it A new national poll from Harvard School of Public Health (HSPH) researchers found that a majority of adults who tried to get the H1N1 vaccine for themselves or their children have been unable to do so. When should flu trigger a school shutdown? As flu season approaches, parents around the country are starting to face school closures. But how bad should an influenza outbreak be for a school to shut down? Common Pain Relievers May Dilute Power of Flu Shots With flu vaccination season in full swing, research from the University of Rochester Medical Center cautions that use of many common pain killers - Advil, Tylenol, aspirin - at the time of injection may blunt the effect of the shot and have a negative effect on the immune system. Initial Results Show Pregnant Women Mount Strong Immune Response To One Dose of 2009 H1N1 Flu Vaccine Healthy pregnant women mount a robust immune response following just one dose of 2009 H1N1 influenza vaccine, according to initial results from an ongoing clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health. Flu vaccine given to women during pregnancy keeps infants out of the hospital Infants born to women who received influenza vaccine during pregnancy were hospitalized at a lower rate than infants born to unvaccinated mothers. Progress made on group B streptococcus vaccine Scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have completed a Phase II clinical study that indicates a vaccine to prevent Group B Streptococcus (GBS) infection is possible. Pandemic flu vaccine campaigns may be undermined by coincidental medical events The effectiveness of pandemic flu vaccination campaigns - like that now underway for H1N1 - could be undermined by the public incorrectly associating coincidental and unrelated health events with the vaccines. Lessons from flu seasons past Pregnant women who catch the flu are at serious risk for flu-related complications, including death, and that risk far outweighs the risk of possible side effects from injectable vaccines containing killed virus, according to an extensive review of published research and data from previous flu seasons. Swine flu vaccine must be free and safe for high uptake Almost half of adults surveyed in Summer 2009 in Hong Kong (45%) say they would take up free swine flu vaccination. More Vaccination Current Events and Vaccination News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||